Prostate Cancer Metastatic research hub
9 indexed studies · 6 currently recruiting
- active not recruitingPHASE1, PHASE2
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
This study is looking into a new medicine, ODM-208, for men with prostate cancer that has spread and is resistant to standard treatments. It aims to see how safe the drug is, what side effects it might cause, and how the body handles it.
United States · Finland · France - active not recruitingPHASE1, PHASE2
A Trial of Ipatasertib in Combination With Atezolizumab
This study looks at combining two medicines, ipatasertib and atezolizumab, for advanced solid tumours and a type of brain tumour called glioblastoma. It aims to find the safest dose and see how well they work together. It's a early-stage study to understand more about these treatments.
United Kingdom - active not recruitingPHASE1, PHASE2
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This study is testing a new drug, ST101, for people with advanced cancers like breast cancer, melanoma, and glioblastoma. It aims to see if the drug is safe, how much to give, and if it could help shrink tumors. It's for adults whose cancer hasn't responded to other treatments.
United States · United Kingdom - recruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
This early-stage study is testing a new type of immunotherapy called CC-38 for people with advanced bowel cancer or prostate cancer. It uses your own immune cells to try and fight the cancer. We want to see if this treatment is safe and effective.
Germany - enrolling by invitationPHASE1, PHASE2
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
This study is for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It tests a new radioactive drug called 177Lu-HTK03170 to find the safest dose and see if it can shrink the cancer.
Canada - recruitingPHASE3
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
This study looks at a new drug, darolutamide, along with standard hormone therapy for men with prostate cancer that has spread. It's for those who might not be able to have other treatments because of their general health.
Belgium · France · Germany - recruitingPHASE2
Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
This study looks at adding focused radiation (MDRT) to usual care for men with advanced prostate cancer that has responded to treatment. It checks if this extra radiation helps lower PSA levels even more and keeps the cancer away for longer.
Canada - recruitingPHASE3
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
This study looks at new treatments for prostate cancer that has spread. It compares two new approaches with the usual care, hoping to improve how long people live and slow the cancer's spread. It's for men aged 18+.
United Kingdom